Bayer AG NA shares rallied roughly 6% to close at €39.30 today after the German life sciences group reported first-quarter 2026 results that exceeded consensus expectations. The standout surprise came from the agricultural business, which provided the decisive boost to quarterly performance.
Underlying operating profit - reported as EBITDA before special items - increased 9% to €4.45 billion for the quarter. Analysts had, on average, been looking for about €3.93 billion. The Q1 2026 results were published at 4:00 AM local time today, triggering broad media coverage soon after.
The agricultural division benefitted materially from a settlement of a licensing dispute with U.S. rival Corteva, which added nearly half a billion euros to revenue. In addition, prices for the weedkiller Dicamba recovered in the U.S., supporting a near 18% rise in segment earnings. Those two factors combined to create the bulk of the upside in Bayer's quarter.
Bayer reiterated its full-year 2026 guidance on a constant currency basis. The company continues to expect annual sales in a range of €44.5 billion to €46.5 billion and EBITDA before special items between €9.4 billion and €9.9 billion. In the company release, CEO Bill Anderson said, "We are continuing to drive the implementation of our strategy forward and are firmly committed to achieving our targets for the current year."
Performance in pharmaceuticals was mixed. The business felt the impact of patent expiries on former blockbusters such as the anticoagulant Xarelto and the eye treatment Eylea. At the same time, sales of newer medicines - including the cancer drug Nubeqa and the kidney treatment Kerendia - showed strong growth. Despite that growth, pharmaceutical earnings fell 7.5%, with the decline attributed primarily to higher distribution costs.
Separately, uncertainty around a series of multi-billion euro glyphosate lawsuits appears to be moving through the U.S. legal system. The U.S. Supreme Court seemed divided during a late-April hearing related to those suits, and a ruling - which market participants note could prove significant for Bayer - is expected by the end of June.
All of this came against a challenging macro backdrop. European equities weakened on Tuesday after hopes for a U.S.-Iran peace deal faded, sending oil prices higher and pushing the STOXX 600 sharply lower. Germany's DAX declined by more than 1% on the day, according to the market data included with the results. Yet Bayer's roughly 6% rise on the day highlights how a strong company-specific earnings beat can overcome broader market headwinds.
The company-level drivers were clear: an agricultural settlement that boosted near-term revenue, recovering Dicamba pricing in the U.S., and reaffirmed full-year guidance. Offsetting these positives were ongoing headwinds in pharmaceuticals from patent expiries and higher distribution costs, plus lingering legal uncertainty over glyphosate litigation outcomes.
Investors will likely watch the upcoming Supreme Court decision and monitor whether agricultural segment momentum and pricing dynamics persist through the rest of the year. For now, Bayer's Q1 results shifted focus back to company fundamentals despite a softening European market pulse.
Disclosure: No disclosure provided.